Drugs / JZP815
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05557045 | Oct 2022 → Apr 2028 expected | metastatic malignant neoplasm | Jazz Pharmaceuticals | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-06-15 | Jazz Pharmaceuticals | Regulatory Jazz Pharmaceuticals and Redx Announce Pan-RAF Inhibitor JZP815 to Enter Clinical Development jazzpharma.com ↗
Clearance of IND application for JZP815 marks fifth Redx product candidate to enter clinical development and triggers USD $5 million milestone payment from Jazz |
| 2022-04-08 | Jazz Pharmaceuticals | Results Jazz Pharmaceuticals Presents Pre-Clinical Data for Pan-RAF Inhibitor JZP815, including Pharmacokinetic Properties and Efficacy in Multiple Solid Tumor Types jazzpharma.com ↗ |
| 2022-03-08 | Jazz Pharmaceuticals | Results Jazz Pharmaceuticals to Present Pan-RAF Inhibitor Pre-Clinical Data at American Association for Cancer Research (AACR) 2022 Annual Meeting jazzpharma.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-06-15 | Jazz Pharmaceuticals | Jazz Pharmaceuticals and Redx Announce Pan-RAF Inhibitor JZP815 to Enter Clinical Development jazzpharma.com ↗ |
| 2022-04-08 | Jazz Pharmaceuticals | Jazz Pharmaceuticals Presents Pre-Clinical Data for Pan-RAF Inhibitor JZP815, including Pharmacokinetic Properties and Efficacy in Multiple Solid Tumor Types jazzpharma.com ↗ |
| 2022-03-08 | Jazz Pharmaceuticals | Jazz Pharmaceuticals to Present Pan-RAF Inhibitor Pre-Clinical Data at American Association for Cancer Research (AACR) 2022 Annual Meeting jazzpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JZP815 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05557045 ↗ |
| Route | Oral | “JZP815 will be administered as oral capsules to participants BID approximately 12 hours apart, in the morning and in the evening.” NCT05557045 ↗ |